CapLaw-2025-32

Sandoz, a global leader in generics and biosimilars, has announced that it has fully repaid USD 750 million equivalent USD and EUR term loans that were put in place in September 2023, just before its spin-off from Novartis. The repayment was funded through proceeds from successful bond transactions: – On 13 March 2025, Sandoz issued a…